Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook

Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook

Steroid-sensitive nephrotic syndrome often follows a relapsing course with a substantial number of patients requiring cytotoxic therapy with cyclophosphamide (CP). However, the long-term success of CP treatment is difficult to predict. We retrospectively evaluated 106 patients after CP to identify p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 2003-07, Vol.18 (7), p.661
Hauptverfasser: Vester, Udo, Kranz, Birgitta, Zimmermann, Stephanie, Hoyer, Peter F
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Age
Age Factors
Alkylating Agents - therapeutic use
Biopsy
Child
Child, Preschool
Cyclophosphamide - therapeutic use
Cytotoxicity
Dose-Response Relationship, Drug
Female
Gender differences
Humans
Infant
Kidney diseases
Leukopenia
Male
Nephrology
Nephrotic Syndrome - drug therapy
Nephrotic Syndrome - epidemiology
Patients
Pediatrics
Prognosis
Recurrence
Regression analysis
Retrospective Studies
Steroids
Steroids - therapeutic use
Success
Survival Analysis
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Steroid-sensitive nephrotic syndrome often follows a relapsing course with a substantial number of patients requiring cytotoxic therapy with cyclophosphamide (CP). However, the long-term success of CP treatment is difficult to predict. We retrospectively evaluated 106 patients after CP to identify parameters associated with sustained remission. The overall rate of cumulative sustained remission was 24% after 10 years. No gender difference was found. Several factors were significantly correlated with the rate of sustained remission: age at CP therapy (remission 34% versus 9% in children older or younger than 5.5 years, P
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-003-1170-9